WAY

Rating neutralTentativeAI MemoPost-earnings T+3

Waystar

As of 2026-08-03/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 results and FY2026 guidance raise • 2026-07-29

Base target: $24 / p=50% prob

Biggest risk

NRR declined to 108% from 111% in Q1, volume-based revenue grew only 3%, and larger deals may require 6-18 months to convert. Stored earnings context also flags heavier software investment and healthcare-utilization uncertainty.

Invalidation

Break below $17 or thesis failure.

What would change my mind?

The Q2 print showed strong revenue growth, 43% adjusted EBITDA margin, subscription expansion, and raised FY2026 guidance. AI and Iodine cross-sell could provide additional recurring growth if adoption converts into reported revenue.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-03

Base target

$24

p=50%

Bull target

$29

p=25%

Bear target

$17

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Subscription growth and retention follow-through
AI and Iodine cross-sell monetization
The Q2 print showed strong revenue growth, 43% adjusted EBITDA margin, subscription expansion, and raised FY2026 guidance.

BearKey bullets

Healthcare coverage, Medicaid enrollment, and uninsured-population changes may affect transaction volumes and provider demand [#PR-EARNINGS-2026-07-30].
Long sales cycles for larger platform deals could delay revenue recognition and weaken near-term visibility [#PR-EARNINGS-2026-07-30].
NRR is at the low end of the company's stated historical 108%-110% range.

WatchKey bullets

Q2 results and FY2026 guidance raise

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $24 (p=50%)

Target spread vs base: +21% / -29%

Scenario probabilities

Bull Target: $29 (p=25%)Base Target: $24 (p=50%)Bear Target: $17 (p=25%)

Commentary

Primary company-source evidence confirms a strong Q2 and raised guidance, but post-print analyst reaction and causal price attribution remain unavailable. The only supplied post-earnings price anchor is $21.11 on July 31. The peer set lacks a verified direct operating comparator, so the report remains a cautious monitoring view.

As of 2026-08-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Subscription growth and retention follow-through
AI and Iodine cross-sell monetization

Scenarios

Bull Target (Scenario probability)

$29 / p=25% prob

Base Target (Scenario probability)

$24 / p=50% prob

Bear Target (Scenario probability)

$17 / p=25% prob

Analysis 2026-08-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-07-29
Q2 results and FY2026 guidance raise
Q2 revenue was $319.7M, up 18% year over year, adjusted EBITDA margin was 43%, and FY2026 revenue and adjusted EBITDA guidance were raised to $1.276B-$1.294B and $535M-$545M, respectively [#SEC-8K-2026-07-29].
Prob 85.00% • Move 8.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Subscription growth and retention follow-through
2026-11-01
Subscription revenue grew 34% year over year to $176.3M and clients generating over $100,000 of revenue rose 15%, but NRR was 108%; sustained growth with stable or improving retention would support multiple recovery [#SEC-8K-2026-07-29].
Prob 55% • Move 10% • Priced-in 35%

Long-term Catalysts

Months to a year

AI and Iodine cross-sell monetization
2026-12-31
Stored earnings-call highlights report more than $6M of bookings from existing clients purchasing Iodine capabilities and early AltitudeAI adoption; durable cross-sell and revenue recovery would strengthen the long-term platform thesis [#PR-EARNINGS-2026-07-30].
Prob 45% • Move 15% • Priced-in 25%

Risks

Healthcare coverage, Medicaid enrollment, and uninsured-population changes may affect transaction volumes and provider demand [#PR-EARNINGS-2026-07-30].
Long sales cycles for larger platform deals could delay revenue recognition and weaken near-term visibility [#PR-EARNINGS-2026-07-30].
NRR is at the low end of the company's stated historical 108%-110% range.
No post-print analyst revisions or rating changes are available in the packet, and the $21.11 July 31 anchor does not by itself establish an earnings-driven market reaction.
Volume-based revenue growth was only 3% year over year, increasing sensitivity to utilization and comparison effects [#SEC-8K-2026-07-29].

Peers

Symbol	Summary
HAE	Same-sector, similar-capitalization candidate from the packet; the packet does not establish direct revenue-cycle software comparability.
ICUI	Same-sector, similar-capitalization candidate from the packet; the packet does not establish direct revenue-cycle software comparability.
CON	Similar-capitalization health-care candidate; the packet does not establish a direct operating match with Waystar's software and transaction-volume model.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-03

Loading AI feed…

Symbol

Summary

HAE

Same-sector, similar-capitalization candidate from the packet; the packet does not establish direct revenue-cycle software comparability.

ICUI

Same-sector, similar-capitalization candidate from the packet; the packet does not establish direct revenue-cycle software comparability.

CON

Similar-capitalization health-care candidate; the packet does not establish a direct operating match with Waystar's software and transaction-volume model.